Quote
257.06
+2.06 (+0.81%)
We have scored 99 news catalysts on ABBV (ABBV) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.42). Most of the impact sits in sector healthcare and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
253.92–259.61
Open
253.92
Prev close
255.00
Volume
4.3M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged ABBV or its network in the window yet.
Show more ABBV articles →Analysts publish price targets on ABBV, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
19 analyst price targets from $235 to $303
as of 2026-09-04
The market is 10% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ABBV — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of ABBV, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ABBV: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The reconstruction
The price sits at the 16th percentile of 19 published models, leaning bearish against the analyst consensus and fully endorsing targets around $260 while refusing to pay for the 15-16% upside that six bull cases require.
What the disagreement turns on
Whether SKYRIZI, RINVOQ, and the neuroscience portfolio can sustain the roughly 11% annual revenue growth the price requires over the next decade, which unit volume data can track but late-stage pipeline catalysts cannot settle with the tools wired here.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
